IJOInternational Journal of Oncology1019-64391791-2423D.A. Spandidos10.3892/ijo.2017.3998ijo-51-01-0307ArticlesTAZ overexpression is associated with epithelial-mesenchymal transition in cisplatin-resistant gastric cancer cellsGeLiang1*LiDong-Song2*ChenFei3FengJi-Dong4LiBai5WangTie-Jun6
Department of Anesthesiology
Department of Surgery, The First Hospital of Jilin University
Abdominal Tumor Medical Department, Jilin Provincial Tumor Hospital
Department of Normal Surgery, Jilin Province Hospital of Traditional Chinese Medicine
Departments of Colorectal and Anal Surgery
Orthopedic Traumatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. ChinaCorrespondence to: Dr Bai Li, Department of Colorectal and Ana Surgery, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, E-mail: bailichangchun@126.comDr Tie-Jun Wang, Department of Orthopedic Traumatology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China, E-mail: tiejunwangjilin@163.com
Gastric cancer is one of the common malignant diseases. The poor treatment outcome is mainly due to chemotherapeutic resistance. Therefore, it is important to determine the molecular mechanism of drug resistance in gastric cancer. To explore the mechanisms of cisplatin resistance in gastric cancer cells, several approaches were performed including MTT assay, real-time RT-PCR, western blot analysis, migration and invasion assays, wound healing assay, and transfection. We found that cisplatin-resistant (CR) gastric cancer cells acquired epithelial-mesenchymal transition (EMT) phenotype. The CR cells with EMT features obtained higher migratory and invasive activities. Moreover, we observed that TAZ was highly expressed in CR cells. Consistently, depletion of TAZ caused partial reversal of EMT to MET in CR cells. Our results suggest that TAZ plays a pivotal role in CR-induced EMT. Targeting TAZ could be a potential therapeutic strategy for gastric cancer.
Gastric cancer is one of the most common malignancies in the United States. There is a decline in gastric cancer occurrence partly due to a lower prevalence of Helicobacter pylori infection because of improved hygiene and a higher consumption of vegetables and lower salt intake (1). However, it is estimated that 28,000 new cases and 10,960 deaths will occur in 2017 in the US (1). In China 679,100 new gastric cancer cases occurred in 2015, being one of the four most common cancers diagnosed (2). Notably, gastric cancer is the second leading cause of cancer death worldwide. Current therapies in clinic mainly include surgery, chemotherapy, and chemoradiation for gastric cancer (3). Although surgery remains the curative therapy, chemotherapy is the important treatment for gastric cancer (4). Due to intrinsic or acquired resistance to chemotherapeutic drug, chemotherapy often fail to achieve effective treatment benefit for gastric cancer patients. Therefore, it is important to determine the molecular mechanism of drug resistance in gastric cancer (5).
Cisplatin has been known as an effective chemotherapeutic drug for the treatment of human malignancies including gastric cancer (6). Cisplatin and fluoropyrimidine-based chemotherapy and trastuzumab have been widely used for advanced stage patients with epidermal growth factor 2 (EGFR2) positivity (7). Unfortunately, cisplatin resistance often occurred during chemotherapeutic treatment (8). Emerging evidence has suggested that drug resistant tumor cells acquired epithelial-mesenchymal transition (EMT) (9). During EMT progress, epithelial cells transit to mesenchymal phenotype, leading to loss of epithelial cell-cell junction and actin cytoskeleton reorganization (10). Subsequently, the expression of epithelial marker E-cadherin was downregulated, but the expression of mesenchymal markers was upregulated, including Vimentin, Snail, Slug, ZEB1 (zinc-finger E-box binding homeobox 1), and ZEB2 (11). A study revealed that chemoresistance to cisplatin induced EMT in human lung adenocarcinoma cells (12). Similarly, another study identified that EMT is associated with cisplatin resistance in gastric cancer cells (13). Furthermore, EMT transcription factor Snail and Slug directly contribute to cisplatin resistance in ovarian cancer cells (14). Although these studies indicated the cisplatin resistance molecular basis, the precise mechanisms of cisplatin resistance are still elusive.
TAZ (transcriptional co-activator with PDZ-binding motif) has been characterized to be involved in gastric tumorigenesis (15). It is known that YAP1 (Yes-associated protein 1) and its paralog TAZ are key factors which are negatively regulated by the Hippo pathway (16). TAZ exerts its oncogenic function through interaction with TEAD transcription factors. Notably, TAZ was highly expressed in gastric cancer samples (17). Strikingly, the expression of TAZ had a close correlation with lymphatic metastasis and tumor TNM (tumor, node, metastasis) stage in gastric cancer (18). Several studies have revealed that TAZ was critically involved in drug resistance in a variety of human cancers (19,20). For instance, taxol resistance is mediated by TAZ and its downstream transcriptional targets Cyr61 and CTGF (connective tissue growth factor) in breast cancer cells (21). Moreover, TAZ promoted EMT and cancer stem cell maintenance in oral cancer (22). Due to TAZ playing a key role in drug resistance and EMT, it is important to determine whether TAZ could regulate drug resistance and EMT in gastric cancer. In the present study, we investigated whether cisplatin-resistant (CR) cells exhibit EMT features in gastric cancer. We also elucidate the role of TAZ in CR-mediated EMT in gastric cancer.
Materials and methodsReagents
MTT [3-(4,5-dimethythiazol- 2-yl)-2,5-diphenyl tetrazolium bromide] was obtained from Sigma (St. Louis, MO, USA). Primary antibodies including anti-TAZ, anti-Vimentin, anti-Snail, anti-Slug, anti-ZO1, anti-E-cadherin, anti-β-catenin, and anti-Tubulin were purchased from Santa Cruz Biotechnology (Santa Cruz, CA, USA). Lipofectamine 2000 and (Roswell Park Memorial Institute) RPMI-1640 medium were purchased from Invitrogen (Carlsbad, CA, USA). The non-specific control siRNA and TAZ siRNA oligonucleotides were purchased from GenePharma (Shanghai, China). Tumor Invasion Assay System was obtained from BD Biosciences (Bedford, MA, USA). Protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA, USA).
Cell culture
Human gastric cancer cell lines MGC803 and SGC7901 were cultured in RPMI-1640 medium supplemented with 5% FBS (fetal bovine serum), penicillin, and streptomycin. Cells were maintained in a humidified 5% CO2 incubator at 37°C. Cells were cultured in medium with increasing concentrations of cisplatin for more than 6 months to establish CR cell lines (23).
MTT assay
The gastric cancer cells were seeded in each well of the 96-well plates. After 24 h incubation, the cells were treated with different concentrations of cisplatin for 72 h. MTT assay was conducted as previously described (24).
Transwell invasion assay
Cell invasion was detected using 24-well inserts with matrigel in 8-µm pores as previously described (24). The invasive activity of cells was detected by using Transwell Invasion kit following the protocol from the manufacturer as previously described (24). Briefly, cells were cultured in the upper chamber of the inserts and RPMI-1600 medium with 10% FBS was added in the lower chamber. After 12 h at 37°C, cells on the upper side of the Transwell were removed. The invading cells on the lower side were fixed and stained with Giemsa solution as well as photographed under a microscope.
Cell attachment and detachment assay
Cell attachment and detachment assays were performed as previously described (25). Briefly, for attachment assay, gastric cancer cells were added in 24-well plates. After 1 h of incubation, we removed the unattached cells and counted the attached cells. For cell detachment assay, after 24 h incubation, the detached cells by 0.05% trypsin digestion for 2 min were counted. The remaining attached cells were trypsinized and counted. The results are presented as a percentage of the attached or detached cells to total cells.
Wound healing assay
The cells were seeded in 6-well plate. After the cells reached >90% confluency, the scratch wound was generated by a pipette tip. After 16 h, photographic images were taken (26).
Reverse transcription-PCR (polymerase chain reaction) analysis for gene expression
The total RNA was isolated with TRIzol (Invitrogen) according to the manufacturer's protocols. The real-time PCR reactions and the primers used in PCR reaction were previously described (24).
Western blot analysis: Cells were lysed with RIPA buffer supplemented with protease inhibitors
The protein concentrations were measured by the Bio-Rad protein assay kit. The same amount of protein samples were separated by SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) and then electrotransferred to the membranes. The membranes were immunoblotted with primary antibodies for western blotting as previously described (27).
Transfection
Gastric cells were seeded in 6-well plates and transfected with TAZ siRNA, or control siRNA (GenePharma) using Lipofectamine 2000 as previously described (24). After the transfection, the cells were applied for further investigation as described under the results section.
Statistical analysis
Statistical analyses were performed to evaluate significance between different groups by GraphPad Prism 5.0 (Graph pad Software, La Jolla, CA, USA). All data were expressed as mean ± SD (standard deviation). P<0.05 was considered to indicate a statistical significant difference.
ResultsEstablishment of cisplatin-resistant gastric cancer cell lines
To determine the acquired function of drug resistant gastric cancer cells, the cisplatin-resistant (CR) gastric cancer cells were established. MGC803 and SGC7901 cells were exposed to low concentration of cisplatin for several days. The dead cells were removed and increasing concentrations of cisplatin were added in culture medium. After gastric cancer cells were cultured for more than 6 months with increasing concentrations of cisplatin, CR cells (MGC803/DDP and SGC7901/DDP) cells were established (23). Our MTT assay showed that 3 µM cisplatin led to approximately 50% cell growth inhibition in both MGC803 and SGC7901 cells (Fig. 1A). Moreover, 4 µM cisplatin treatment caused more than 60% and 80% growth inhibition in MGC803 and SGC7901 cells, respectively (Fig. 1A). However, 2 µM cisplatin did not inhibit cell growth in both CR cells (Fig. 1A). The resistant cells were continuously cultured in medium with 2 µM cisplatin for the following study.
CR cells exhibit EMT features
It has been documented that drug resistant cells acquired EMT phenotype (28,29). In line with this concept, MGC803/DDP and SGC7901/DDP cells displayed morphologic changes, such as EMT phenotype. Both MGC803/DDP and SGC7901/DDP cells become elongated, and fibroblastoid in morphology, whereas MGC803 and SGC7901 were a rounded shape (Fig. 1B). EMT-type cells often have aggressive characteristics. Our Transwell invasion assay showed that the numbers of invasive cells were increased in CR cells compared with parental cells (Fig. 1C). Consistently, CR cells exhibited enhanced capacity of detachment and attachment (Fig. 1D). Similarly, our wound healing assay results demonstrated that CR cells acquired increased motility activity (Fig. 2A). Altogether, CR cells acquired EMT characteristics.
CR cells have EMT molecular marker changes
To further confirm whether CR cells acquired EMT, we detected the expression of EMT molecular markers in CR cells and their parental cells, including N-cadherin, E-cadherin, Vimentin, Slug, and ZO-1. Our real-time RT-PCR results indicated that the expression of E-cadherin and ZO-1 was downregulated in CR cells, whereas the levels of N-cadherin, Vimentin, and Slug were upregulated in CR cells (Fig. 2B). Importantly, our western blotting data validated that epithelial molecules were decreased in CR cells, but mesenchymal markers were increased in CR cells (Fig. 3). These findings suggest that CR cells acquired a mesenchymal feature.
Overexpression of TAZ in CR cells
Several studies have revealed that TAZ is associated with EMT in cancers (30,31). To determine whether TAZ was involved in CR-induced EMT process, real-time RT-PCR and western blotting were performed to measure the transcription and translation levels of TAZ in CR cells. We observed that both mRNA and protein levels of TAZ were significantly upregulated in CR cells (Fig. 4A). Notably, Notch1, a target of TAZ, was also increased (Fig. 4A). We also found that β-catenin is highly expressed in CR cells (Fig. 4A). Therefore, our results displayed that the acquisition of EMT might be due to higher expression of TAZ in CR cells.
Depletion of TAZ reverses EMT to MET in CR cells
To further dissect the role of TAZ in CR-triggered EMT, we knocked down the expression of TAZ in CR cells. Our TAZ siRNAs significantly downregulated the expression of TAZ in CR cells (Fig. 4B). We selected TAZ siRNA3 for the following study. We found that depletion of TAZ reverses EMT to mesenchymal-epithelial transition (MET) in CR cells (Fig. 4C). Noteworthy, downregulation of TAZ decreased cell attachment and detachment activities (Fig. 4D). These data suggest that TAZ plays an essential role in CR-induced EMT.
Depletion of TAZ retards motility and invasion in CR cells
To deeper define the function of TAZ in CR cells, Transwell invasion assay was conducted. Our invasion results displayed that downregulation of TAZ significantly inhibited cell invasion in CR cells (Fig. 5A). In support of this, our wound healing assay showed that depletion of TAZ reduced cell motility in CR cells (Fig. 5B). Therefore, TAZ plays an important role in regulation of cell migration and invasion in CR cells.
Depletion of TAZ regulates expression of EMT markers
Next, we explore whether knockdown of TAZ could regulate the expression of EMT markers. To achieve this goal, the mRNA and protein levels of EMT markers were measured by real-time RT-PCR and western blotting, respectively. We found that downregulation of TAZ increased the expression of epithelial markers, but decreased the level of mesenchymal markers (Figs. 5C and 6A and B). Therefore, these results further confirmed the role of TAZ in regulation of EMT in CR cells.
Downregulation of TAZ enhances CR cells to cisplatin sensitivity
To determine whether depletion of TAZ expression enhances CR cells to cisplatin sensitivity, MTT assay was used to detect the cell growth in TAZ siRNA transfected CR cells. We observed that downregulation of TAZ significantly attenuated cell growth inhibition approximately 20–30% induced by 2 µM cisplatin (Fig. 6C). These MTT results implied that downregulation of TAZ could enhance CR cells to cisplatin-induced cell growth inhibition.
Discussion
Gastric cancer is the fourth most common cancer worldwide. Since chemotherapy often has treatment failure due to drug resistance, it is pivotal to explore the mechanisms of chemotherapy resistance in gastric cancer. It is clear that reasons of drug resistance are complex and multifactorial. Thus, it is necessary to define the mechanisms of chemoresistance in gastric cancer (23). In the present study, we aimed to elucidate the molecular basis of chemoresistance in gastric cancer. We observed that cisplatin-resistant (CR) gastric cancer cells obtained EMT features, leading to enhanced motility and invasion. Mechanistically, higher expression of TAZ was found in CR cells. Moreover, depletion of TAZ reversed CR-induced EMT to MET. Our findings demonstrated that TAZ plays a critical role in chemoresistance and EMT in gastric cancer cells. Therefore, inhibition of TAZ could be a promising approach to overcome cisplatin resistance in gastric cancer.
Emerging evidence has demonstrated that chemoresistant cancer cells are associated with EMT (32). For example, gemcitabine-resistant pancreatic cancer cells displayed EMT via upregulation of Notch signaling pathway (33). Another study showed that gemcitabine-resistant hepatocellular carcinoma cells underwent EMT process through activation of PDGF-D pathway (24). Cisplatin resistance in gastric cancer cells is correlated with Her2 upregulation-induced EMT (34). CR cervical cancer cells exhibited EMT phenotype and overexpression of Sema4C (35). Consistent with these findings, our current study revealed that CR gastric cancer cells acquired EMT phenotype with decreased E-cadherin and increased expression of mesenchymal markers including Snail, Slug, Vimentin, and N-cadherin. Notably, EMT-type cells exhibited higher activities of migration and invasion. We confirmed that CR gastric cancer cells are associated with EMT.
Multiple studies have elucidated that some signaling pathways controlled cisplatin-induced chemoresistance. Sun et al found that NF-κB signaling played irreplaceable roles in cisplatin-induced chemoresistance and tumor progression in bladder cancer (36). Liu et al reported that cisplatin resistance is associated with increased motility and stem-like properties through upregulation of STAT3/Snail axis in tumor cells (37). One study showed that SET-mediated NDRG1 inhibition is involved in cisplatin resistance and EMT in human lung cancer cells (38). Another study demonstrated that Fbw7 upregulation promoted cisplatin cytotoxicity in non-small cell lung cancer cells (39). Wang et al reported that Akt/β-catenin/Snail signaling pathway was associated with CR induced EMT in lung cancer cells (40). Downregulation of Par-4 conferred cisplatin resistance through PI3K (phosphoinositide 3-kinase)/Akt pathway-dependent EMT in pancreatic cancer cells (41). Connexin 43 has been found to reverse the resistance of lung adenocarcinoma cells to cisplatin through inhibition of EMT (42). Further study revealed that prolonged pemetrexed pretreatment enhanced persistence of cisplatin-induced DNA damage and eliminated tumor cells with EMT and cancer stem-like features in lung cancer cells (43). Our study identified that TAZ governed the CR-mediated EMT in gastric cancer cells. Further investigation is required to explore how TAZ controls CR-induced EMT in gastric cancer.
Accumulating evidence has demonstrated that miRNAs play an essential role in drug resistance and EMT in human cancers. For example, it has been observed that miR-20a induced cisplatin resistance via targeting CYLD in human gastric cancer cells (44). Zhao et al found that miR-181a suppressed autophagy and sensitized gastric cancer cells to cisplation (45). In addition, miR-26a enhanced the sensitivity of gastric cancer cells to cisplatin through targeting NRAS and E2F2 (46). Several miRNAs regulated the cisplatin resistance of human gastric cancer cells. Importantly, Chen et al reported that miR-206 regulated cisplatin resistance and EMT partly by targeting MET in human lung cancer cells (12). Wang et al found that miR-30a modulated EMT and cisplatin sensitivity in gastric cancer cells (13). Zuo et al identified that miR-141 inhibited tumor growth and metastasis via directly targeting TAZ in gastric cancer studies (47). These reports indicated that regulation of these miRNAs could be helpful to govern cisplatin-induced EMT.
In summary, our study validated that CR gastric cells acquired EMT in part due to overexpression of TAZ. In addition, consistent with other study (26,48), TAZ was found to increase the expression of Notch-1 and β-catenin. Notch-1 and Wnt/β-catenin have been characterized as the drivers to induce EMT (33,49). Therefore, we believe that TAZ-induced EMT could be partly through upregulation of Notch-1 and β-catenin. Our results also indicated that downregulation of TAZ could be a useful strategy for restoring sensitivity to cisplatin. Indeed, one study has shown that knockdown of TAZ modified breast cancer cell sensitivity to EGFR inhibitors (50). In line with this, we found that depletion of TAZ sensitized CR cells to cisplatin treatment. Interestingly, one natural compound, curcumin, has been reported to inhibit the expression of TAZ in bladder cancer cells (51) and pancreatic cancer cells (48). Due to non-toxic nature of natural agents, inhibition of TAZ by these compounds could be a safe and effective approach for the prevention and the treatment of gastric cancer.
Acknowledgments
We thank our colleague for their critical reading.
ReferencesSiegelRLMillerKDJemalACancer Statistics, 2017CA Cancer J Clin67730201710.3322/caac.2138728055103ChenWZhengRBaadePDZhangSZengHBrayFJemalAYuXQHeJCancer statistics in China, 2015CA Cancer J Clin66115132201610.3322/caac.2133826808342HayakawaYSethiNSepulvedaARBassAJWangTCOesophageal adenocarcinoma and gastric cancer: Should we mind the gap?Nat Rev Cancer16305318201610.1038/nrc.2016.2427112208LordickFJanjigianYYClinical impact of tumour biology in the management of gastroesophageal cancerNat Rev Clin Oncol13348360201610.1038/nrclinonc.2016.1526925958WadhwaRSongSLeeJSYaoYWeiQAjaniJAGastric cancer-molecular and clinical dimensionsNat Rev Clin Oncol10643655201310.1038/nrclinonc.2013.170240610393927982PetrelliFZaniboniACoinuACabidduMGhilardiMSgroiGBarniSCisplatin or not in advanced gastric cancer: A systematic review and meta-analysisPLoS One8e83022201310.1371/journal.pone.0083022OrdituraMGaliziaGSforzaVGambardellaVFabozziALaterzaMMAndreozziFVentrigliaJSavastanoBMabiliaATreatment of gastric cancerWorld J Gastroenterol2016351649201410.3748/wjg.v20.i7.1635245876433930964ChenDJChenWJiangHYangHWangYCChenJHDownregulation of DOCK1 sensitizes bladder cancer cells to cisplatin through preventing epithelial-mesenchymal transitionDrug Des Devel Ther1028452853201610.2147/DDDT.S101998276604155019270DuBShimJSTargeting epithelial-mesenchymal transition (EMT) to overcome drug resistance in cancerMolecules2121201610.3390/molecules21070965De CraeneBBerxGRegulatory networks defining EMT during cancer initiation and progressionNat Rev Cancer1397110201310.1038/nrc344723344542ThieryJPAcloqueHHuangRYNietoMAEpithelial-mesenchymal transitions in development and diseaseCell139871890200910.1016/j.cell.2009.11.00719945376ChenQYJiaoDMWangJHuHTangXChenJMouHLuWmiR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting METOncotarget724510245262016270149105029718WangLLZhangXHZhangXChuJKMiR-30a increases cisplatin sensitivity of gastric cancer cells through suppressing epithelial-to-mesenchymal transition (EMT)Eur Rev Med Pharmacol Sci2017331739201627212164HaslehurstAMKotiMDharseeMNuinPEvansKGeraciJChildsTChenJLiJWeberpalsJEMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancerBMC Cancer1291201210.1186/1471-2407-12-91224298013342883KangWChengASYuJToKFEmerging role of Hippo pathway in gastric and other gastrointestinal cancersWorld J Gastroenterol2212791288201610.3748/wjg.v22.i3.1279268116644716037HongAWMengZGuanKLThe Hippo pathway in intestinal regeneration and diseaseNat Rev Gastroenterol Hepatol13324337201610.1038/nrgastro.2016.5927147489YueGSunXGimenez-CapitanAShenJYuLTeixidoCGuanWRosellRLiuBWeiJTAZ is highly expressed in gastric signet ring cell carcinomaBioMed Res Int2014393064201410.1155/2014/393064247074833953576ZhouGXLiXYZhangQZhaoKZhangCPXueCHYangKTianZBEffects of the hippo signaling pathway in human gastric cancerAsian Pac J Cancer Prev1451995205201310.7314/APJCP.2013.14.9.519924175801KimMHKimJHongHLeeSHLeeJKJungEKimJActin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activationEMBO J35462478201610.15252/embj.2015920814772854TianTLiALuHLuoRZhangMLiZTAZ promotes temozolomide resistance by upregulating MCL-1 in human glioma cellsBiochem Biophys Res Commun463638643201510.1016/j.bbrc.2015.05.11526043698LaiDHoKCHaoYYangXTaxol resistance in breast cancer cells is mediated by the hippo pathway component TAZ and its downstream transcriptional targets Cyr61 and CTGFCancer Res7127282738201110.1158/0008-5472.CAN-10-271121349946LiZWangYZhuYYuanCWangDZhangWQiBQiuJSongXYeJThe Hippo transducer TAZ promotes epithelial to mesenchymal transition and cancer stem cell maintenance in oral cancerMol Oncol910911105201510.1016/j.molonc.2015.01.00725704916YangQHuangJWuQCaiYZhuLLuXChenSChenCWangZAcquisition of epithelial-mesenchymal transition is associated with Skp2 expression in paclitaxel-resistant breast cancer cellsBr J Cancer11019581967201410.1038/bjc.2014.136246426273992499WuQWangRYangQHouXChenSHouYChenCYangYMieleLSarkarFHChemoresistance to gemcitabine in hepatoma cells induces epithelial-mesenchymal transition and involves activation of PDGF-D pathwayOncotarget419992009201310.18632/oncotarget.1471241585613875765KongDWangZSarkarSHLiYBanerjeeSSaligananAKimHRCherMLSarkarFHPlatelet-derived growth factor-D overexpression contributes to epithelial-mesenchymal transition of PC3 prostate cancer cellsStem Cells2614251435200810.1634/stemcells.2007-1076184037543766351ZhaoZZhengNWangLHouYZhouXWangZRottlerin exhibits antitumor activity via down-regulation of TAZ in non-small cell lung cancerOncotarget87827783820175352364TanYQinSHouXQianXXiaJLiYWangRChenCYangQMieleLProteomic-based analysis for identification of proteins involved in 5-fluorouracil resistance in hepatocellular carcinomaCurr Pharm Des208187201410.2174/138161282001140113125143WangZLiYAhmadABanerjeeSAzmiASKongDSarkarFHPancreatic cancer: Understanding and overcoming chemoresistanceNat Rev Gastroenterol Hepatol82733201110.1038/nrgastro.2010.188MalliniPLennardTKirbyJMeesonAEpithelial-to-mesenchymal transition: What is the impact on breast cancer stem cells and drug resistanceCancer Treat Rev40341348201410.1016/j.ctrv.2013.09.008XieDCuiJXiaTJiaZWangLWeiWZhuAGaoYXieKQuanMHippo transducer TAZ promotes epithelial mesenchymal transition and supports pancreatic cancer progressionOncotarget635949359632015264164264742153XiaoHJiangNZhouBLiuQDuCTAZ regulates cell proliferation and epithelial-mesenchymal transition of human hepatocellular carcinomaCancer Sci106151159201510.1111/cas.125874399022PiskarevaOHarveyHNolanJConlonRAlcockLBuckleyPDowlingPHenryMO'SullivanFBrayIThe development of cisplatin resistance in neuroblastoma is accompanied by epithelial to mesenchymal transition in vitroCancer Lett364142155201510.1016/j.canlet.2015.05.00425960282WangZLiYKongDBanerjeeSAhmadAAzmiASAliSAbbruzzeseJLGallickGESarkarFHAcquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathwayCancer Res6924002407200910.1158/0008-5472.CAN-08-4312192763442657919HuangDDuanHHuangHTongXHanYRuGQuLShouCZhaoZCisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transitionSci Rep620502201610.1038/srep20502268463074742832SongJLiYmiR-25-3p reverses epithelial-mesenchymal transition via targeting Sema4C in cisplatin-resistance cervical cancer cellsCancer Sci1082331201710.1111/cas.13104SunYGuanZLiangLChengYZhouJLiJXuYNF-κB signaling plays irreplaceable roles in cisplatin-induced bladder cancer chemoresistance and tumor progressionInt J Oncol482252342016LiuWHChenMTWangMLLeeYYChiouGYChienCSHuangPIChenYWHuangMCChiouSHCisplatin-selected resistance is associated with increased motility and stem-like properties via activation of STAT3/Snail axis in atypical teratoid/rhabdoid tumor cellsOncotarget617501768201510.18632/oncotarget.2737256381554359329LiuHGuYYinJZhengGWangCZhangZDengMLiuJJiaXHeZSET-mediated NDRG1 inhibition is involved in acquisition of epithelial-to-mesenchymal transition phenotype and cisplatin resistance in human lung cancer cellCell Signal2627102720201410.1016/j.cellsig.2014.08.01025152373YuHGWeiWXiaLHHanWLZhaoPWuSJLiWDChenWFBW7 upregulation enhances cisplatin cytotoxicity in non-small cell lung cancer cellsAsian Pac J Cancer Prev1463216326201310.7314/APJCP.2013.14.11.6321WangHZhangGZhangHZhangFZhouBNingFWangHSCaiSHDuJAcquisition of epithelial-mesenchymal transition phenotype and cancer stem cell-like properties in cisplatin-resistant lung cancer cells through AKT/β-catenin/Snail signaling pathwayEur J Pharmacol723156166201410.1016/j.ejphar.2013.12.004TanJYouYXuTYuPWuDDengHZhangYBiePPar-4 downregulation confers cisplatin resistance in pancreatic cancer cells via PI3K/Akt pathway-dependent EMTToxicol Lett224715201410.1016/j.toxlet.2013.10.008YuMZhangCLiLDongSZhangNTongXCx43 reverses the resistance of A549 lung adenocarcinoma cells to cisplatin by inhibiting EMTOncol Rep3127512758201424789679TiècheCCPengRWDornPFromentLSchmidRAMartiTMProlonged pemetrexed pretreatment augments persistence of cisplatin-induced DNA damage and eliminates resistant lung cancer stem-like cells associated with EMTBMC Cancer16125201610.1186/s12885-016-2117-4268959544759918ZhuMZhouXDuYHuangZZhuJXuJChengGShuYLiuPZhuWmiR-20a induces cisplatin resistance of a human gastric cancer cell line via targeting CYLDMol Med Rep1417421750201627357419ZhaoJNieYWangHLinYMiR-181a suppresses autophagy and sensitizes gastric cancer cells to cisplatinGene576828833201610.1016/j.gene.2015.11.013WenLChengFZhouYYinCMiR-26a enhances the sensitivity of gastric cancer cells to cisplatin by targeting NRAS and E2F2Saudi J Gastroenterol21313319201510.4103/1319-3767.166206264588594632257ZuoQFZhangRLiBSZhaoYLZhuangYYuTGongLLiSXiaoBZouQMMicroRNA-141 inhibits tumor growth and metastasis in gastric cancer by directly targeting transcriptional co-activator with PDZ-binding motif, TAZCell Death Dis6e1623201510.1038/cddis.2014.573256332924669771ZhouXSuJFengSWangLYinXYanJWangZAntitumor activity of curcumin is involved in down-regulation of YAP/TAZ expression in pancreatic cancer cellsOncotarget779076790882016277383255346699ZhangJTianXJXingJSignal transduction pathways of EMT induced by TGF-β, SHH, and WNT and their crosstalksJ Clin Med55201610.3390/jcm5040041GuoLZhengJZhangJWangHShaoGTengLKnockdown of TAZ modifies triple-negative breast cancer cell sensitivity to EGFR inhibitors by regulating YAP expressionOncol Rep36729736201627373987GaoYShiQXuSDuCLiangLWuKWangKWangXChangLSHeDCurcumin promotes KLF5 proteasome degradation through downregulating YAP/TAZ in bladder cancer cellsInt J Mol Sci151517315187201410.3390/ijms150915173251708064200832
Cisplatin-resistant (CR) cells exhibited EMT phenotype. (A) MTT assay was conducted in parental and CR gastric cancer cells. *P<0.05, **P<0.01 vs. control. (B) Cell morphology was observed by microscopy in parental and CR cells. Parental MGC803 and SGC7901 cells displayed an epithelioid appearance, whereas their CR cells showed elongated, irregular fibroblastoid morphology. (C) Invasion assay was performed to measure the invasive capacity in parental and CR cells. *P<0.05 vs. control. (D) Cell attachment and attachment assays were assessed in parental and CR cells. *P<0.05, **P<0.01 vs. control.
Cisplatin-resistant (CR) cells have enhanced motility activity. (A) Wound assays were performed in parental and CR cells. (B) Real-time RT-PCR assay was conducted to detect the expression of EMT markers in parental and CR cells. *P<0.05 CR, **P<0.01 vs. control. Ctrl, control.
Cisplatin-resistant (CR) cells have EMT marker changes. (A) Western blot analysis was used to detect the expression of E-cadherin, Snail, Slug, and Vimentin in MGC803 and MGC803 CR cells. Ctrl, control. (B) Quantitative results are illustrated for (A). *P<0.05, **P<0.01 vs. control. (C) Western blot analysis was performed to measure the expression of E-cadherin, Snail, Slug, and Vimentin in SGC7901 and SGC7901 CR cells. (D) Quantitative results are illustrated for (C). *P<0.05, **P<0.01 vs. control.
Cisplatin-resistant (CR) cells have high expression of TAZ. (A, left panel) Real-time RT-PCR assay was conducted to detect the expression of TAZ in parental and CR cells. *P<0.05 CR vs. control siRNA. (A, right panel) Western blot analysis was performed to detect the expression of TAZ in parental and CR cells. (B) Western blot analysis was performed to detect the efficacy of TAZ siRNA transfection. (C) Cell morphology was assessed by microscopy in CR cells transfected with TAZ siRNA. (D) Cell attachment and detachment assays were measured in CR cells transfected with TAZ siRNA. *P<0.05, **P<0.01 vs. control. CS, control siRNA; TS, TAZ siRNA.
Depletion of TAZ inhibits motility and invasion and regulates expression of EMT markers in cisplatin-resistant (CR) cells. (A, top panel) Invasion assays were performed in CR cells transfected with TAZ siRNA. (A, bottom panel) Quantitative results are illustrated for the top panel. *P<0.05 vs. control siRNA. (B) Wound healing assays were used to detect the motility in CR cells transfected with TAZ siRNA. (C) Western blot analysis was used to detect the expression of EMT markers in CR cells transfected with TAZ siRNA. CS, control siRNA; TS, TAZ siRNA.
Depletion of TAZ regulates mRNA levels of EMT markers in cisplatin-resistant (CR) cells. (A and B) Real-time RT-PCR was performed to quantify mRNA expression of EMT markers in CR cells transfected with TAZ siRNA. CS, control siRNA; SS, TAZ siRNA. *P<0.05, **P<0.01 compared with control siRNA. (C) MTT assay was performed in CR cells treated with TAZ siRNA. CS: control siRNA; TS: TAZ siRNA. *P<0.05, **P<0.01 compared with control siRNA.